Much more than a ‘party drug’

Psilocybin, MDMA or LSD might associate with party drugs but their therapeutic value is being discovered worldwide. Ian Roullier took part in two clinical trials that looked at the effects of psilocybin on depression. Through his personal experience, Roullier shares his insights on psychedelic-assisted therapy, its potential value to patients and what is needed to boost research in this field.